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ABSTRACT
RECQ helicases are a family of enzymes with both over lapping and unique 
functions. Functional autosomal recessive loss of three members of the family BLM, 
WRN and RECQL4, results in hereditary human syndromes characterized by cancer 
predisposition and premature aging, but despite the finding that RECQL5 deficient 
mice are cancer prone, no such link has been made to human RECQL5. Here we 
demonstrate that human urothelial carcinoma of the bladder (UCC) has increased 
expression of RECQL5 compared to normal bladder tissue and that increasing RECQL5 
expression can drive proliferation of normal bladder cells and is associated with poor 
prognosis. Further, by expressing a helicase dead RECQL5 and by depleting bladder 
cancer cells of RECQL5 we show that inhibition of RECQL5 activity has potential as a 
new target for treatment of UCC.
INTRODUCTION
Urothelial carcinoma of the bladder (UCC) is the 
fourth most common cancer in men and seventh most 
common in women, affecting more than 400,000 people 
world wide annually [1]. Around 1/3 of cancers are high 
grade and have a poor prognosis when invading into the 
bladder wall. The median survival for muscle invasive 
cancers is around 50% and has not improved in recent years, 
since the introduction of platinum based therapies [2–4]. 
Currently there is no treatment able to increase survival after 
platinum failure, thus there is an urgent need to develop new 
and effective agents. Molecular changes such as altered gene 
expression, have potential as targets to increase therapeutic 
response to conventional chemotherapies or as stand-
alone agents. There has been some success in identifying 
molecular targets for therapy in UCC [5–7], which have lead 
to several current clinical trials [8, 9], however to date none 
have progressed to standard care.
Genomic stability plays a key role in preventing 
tumourigenesis and instability is a key hallmark of cancer 
[10]. Alterations in the pathways responsible for maintain 
genomic instability can influence tumour development 
and response to therapy, while the same pathways can 
be themselves targets for therapy [11–15]. The RECQ 
helicases are conserved throughout evolution and 
contribute to genome stability through roles in replication, 
base excision repair, double-strand break repair, 
transcription, telomere maintenance and mitochondrial 
function [16]. All family members share a homologous 
helicase and RecQ C-Terminal domain, which contains 
a zinc-binding motif, a helix-hairpin-helix winged-helix 
domain and a β-hairpin motif. There are 5 mammalian 
RECQ helicases, RECQL (RECQ1), BLM (RECQ2), 
WRN (RECQ3), RECQL4, and RECQL5, having some 
over lapping and some distinct functions. Functional 
autosomal recessive loss of BLM, WRN and RECQL4, 
results in hereditary human syndromes characterized by 
cancer predisposition and premature aging (Bloom’s, 
Werner’s, and Rothmund-Thomson’s syndromes, 
respectively) [17]. Further a number of polymorphisms 
are identified for the RECQ helicases that can determine 
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survivability and susceptibility to cancers [18–24] and 
recently we demonstrated that increased expression of 
RECQL5 can be associated to poor prognosis in breast 
cancer [25]. While no hereditary disease is associated 
with RECQL5, deficient mice display high levels of 
spontaneous double strand breaks, are susceptible to 
gross chromosomal rearrangements and are prone to 
develop lymphomas and various solid tumours [26, 27], 
suggesting RECQL5 could also play a role in preventing 
tumourigenesis. In support of this RECQL5 is reported to 
have roles in suppression or repair of endogenous DNA 
damage [28–30], and in overcoming/repairing damage 
induced by DNA crosslinks [31–34], thymidine [35], 
hydroxyurea [33], camptothecin [34, 36] and transcription-
replication collisions [37–40]. RECQL5 has 3 isoforms α, 
β and γ. While all 3 isoforms contain the helicase domain 
only the β isoform is nuclear [41] and it is this form which 
is generally considered as being involved in the cellular 
DNA damage response pathway. For the most part in this 
work specifically RECQL5β is considered while reference 
to RECQL5 infers no specific isoform is being implicated.
We demonstrate that UCC have increased expression 
of RECQL5β compared to normal bladder tissue and that 
increasing RECQL5β expression can drive proliferation 
of normal bladder cells. Further by using a helicase dead 
RECQL5β we show that inhibition of RECQL5 activity is 
a potential new target for treatment of UCC.
RESULTS
Primary UCCs have significantly increased 
expression of RECQL5 helicase protein
Expression of RECQL5 helicase protein was 
analysed in 98 sporadic primary human UCC samples 
and 52 normal bladder tissue (Supplementary Table S1) 
using an antibody specific to RECQL5β (Supplementary 
Figure S1). Tissues were scored for strength of nuclear 
staining (Figure 1A). There was a highly significant 
increase in nuclear staining of RECQL5 in the malignant 
samples (Figure 1B, Contingency Table Pearson Chi-
square test P=3.7x10e-17), with 90% of the malignant 
bladder samples scoring positive for RECQL5β compared 
to normal bladder samples where 83% of samples were 
negative for any nuclear staining. Tumour Samples were 
then grouped by stage and grade and RECQL5 intensity 
compared (Supplementary Figure S2). No significant 
difference in degree of RECQL5β expression was seen 
between tumour samples of differing stage (Contingency 
Table Pearson Chi-square test P=0.953), and suggestive 
evidence of expression with higher-grade metastatic 
disease was seen but only when samples were grouped 
by staining vs. non-staining (Contingency Table Pearson 
Chi-square test P = 0.035). A small number of tumour 
adjacent normal samples were also analysed (Figure 2), 
no significant difference was detected most likely due to 
sample size however a trend to more RECQL5 staining 
compared to normal can be argued. Interestingly a few 
malignant samples (n=3) and no normal samples displayed 
additional cytoplasmic staining for RECQL5β, however 
numbers are too low to determine significance (data not 
shown).
Consistent with this western blotting revealed 
that three UCC cell lines, EJ, RT112 and RT4, have 
significantly higher levels of RECQL5β protein expression 
when compared to an immortalised normal bladder cell 
line, NHU hTERT (Figure 1C&1D - Student’s t-test, p 
values = 2.1 × 10-3, 4.4 × 10-2 and 4.1 × 10-2 respectively).
The number of RECQL5 foci in cells has been 
shown to vary throughout the cell cycle and it’s expression 
is moderately increased following replication stress [35]. 
However when comparing UCC and normal bladder cell 
lines there was no significant difference in the percentage 
of cells in each phase of the cell cycle (Supplementary 
Figure S3) suggesting that differences in expression are 
tumour specific rather than cell cycle related. To further 
examine this in patient samples, a number of UCC tumour 
sections were stained for Ki67 in parallel to RECQL5; 
high RECQL5 staining could be seen with or without 
Ki67 staining, confirming that RECQL5 expression in 
tumours is not due only to increased cellular proliferation 
(Supplementary Figure S4). Finally in support of the 
change being unrelated altered proliferation, previous 
studies where RECQL5 was knocked out using gene 
distruption in DT40 cells, pulse labeling with BrdU 
staining demonstrated that the fraction of cells in S-phase 
is unaltered [32].
Aggressive UCC has significantly increased 
levels of RECQL5 mRNA, which are associated 
with worse survival
Expression of RECQL5 mRNA was analysed in 
197 primary UCC samples and 20 normal tissue samples 
(Supplementary Table S2). There was a significant increase 
in RECQL5 mRNA levels in the bladder cancers compared 
to the normal bladder tissue (Figure 2A – Student’s t.test 
p<0.001). A similar but less significant (p=0.03) result 
was found when using a probe that specifically recognises 
RECQL5β (data not shown). When tumours were stratified 
by grade, RECQL5 expression seemed highest in those of 
high grade but that were not yet invasive (Figure 2B – 
Student’s t.test p=0.04). This is consistent with survival 
analysis whereby high RECQL5 mRNA was associated 
with reduced progression free survival (Figure 2C – log-
rank test p=0.028).
Depletion of RECQL5 specifically reduces 
proliferation of UCC cells
Cancer specific overexpression of a protein 
represents a potential site of therapeutic intervention. 
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Figure 1: RECQL5 protein expression is increased in UCC. A. Tissue microarray stained for RECQL5β and scored on a scale 
of 0-3 depending on whether the nuclear staining was negative, weak, medium, or strong respectively. Examples of normal and malignant 
tissue in each category are shown. None of the normal samples had medium or strong staining. B. Quantification of staining and statistical 
significance calculated using Contingency Table Pearson Chi-square test. C. Western blot for RECQL5β in normal immortalised bladder 
(NHU hTERT) and UCC (EJ, RT4, and RT112) cells; 2 successive passages of the cells are shown. D. Quantification of western blots 
average and standard deviation of 4 biological repeats is shown, * and ** indicate p<0.05 and p<0.01 respectively using Students t-test.
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Figure 2: RECQL5 mRNA is increased in UCC and is associated with poor prognosis. Taqman qRT-PCR quantification 
of mRNA from 197 primary bladder tumour and 20 normal tissue samples using a RECQL5 probe and plotted as fold change [52]. A. 
Stratified by normal compared to malignant tissue and B. according to tumour grade; * and *** indicate p<0.05 and p<0.001 respectively 
using Students t-test C. Kaplan Meier curve showing progression free survival based on RECQL5 mRNA expression, p value calculated 
as log-rank score.
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To test whether RECQL5 is such a target, UCC and 
normal bladder cells were depleted of RECQL5 
protein using siRNA (Figure 3A). Ninety six hours 
post transfection the relative survival of bladder cancer 
cells depleted of either all isoforms of RECQL5 (si1) 
or specifically RECQL5β (si2) was significantly 
reduced (Student’s t-test, p value = 5.1 × 10-3 and 
3.5 × 10-3 respectively), while the survival of normal 
bladder cells was not affected (Figure 3B), suggesting 
that RECQL5 could be a cancer specific target for 
therapeutic intervention in UCC. It has been reported 
that RECQL5 is involved in recovery from DNA cross-
links [31–34] and camptothecin [34, 36] induced DNA 
damage. Here depletion of RECQL5 (using a pool 
of RECQL5 si1 and si2) reduced UCC cell survival 
following treatment with the DNA cross-linking agent 
MMC or the topoisomeraise inhibitor camptothecicn 
compared to treatment with the DNA damaging alone 
(Figure 3C), suggesting combination therapy could be 
beneficial.
Figure 3: Depletion of RECQL5 reduces survival in bladder cancer cells. A. Western blot for RECQL5β of UCC (EJ) and 
immortalised normal bladder (NHU hTERT) cells depleted of RECQL5 using siRNA against RECQL5β specifically (Q5 si1) or all 3 
isoforms of RECQL5 (Q5 si2) compared to cells treated with non-targeting control (SC) siRNA. B. Survival fraction of corresponding 
RECQL5 depleted cells 96 h post siRNA transfection. C. Survival fraction of siRNA treated cells treated with or without 25 nM camptothecin 
(CPT) or 100 nM mitomycin C (MMC). Average and standard deviation of at least 3 experiments is shown, * and ** indicate p<0.05 and 
p<0.01 respectively using Students t-test, ns = not significant.
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Exogenous expression of a helicase dead RECQL5 
reduces proliferation and sensitizes to replication 
stress in UCC cells while expression of RECQL5 
increases proliferation in normal bladder cells
UCC and normal bladder cells were transiently 
transfected with wildtype (Q5) or helicase dead (Q5KR) 
RECQL5β (Figure 4D). As UCC cells proliferate faster 
than normal bladder cells the relative effect of expression 
of Q5 and Q5KR was compared after 3 cell doublings 
which corresponded to 48 h for UCC and 96 h for normal 
bladder cells. Proliferation of Q5KR transfected UCC 
cells (EJ) was significantly decreased compared to Q5 
or empty vector (EV) transfected cancer cells (Figure 
4A&4C) (Student’s t-test, p value = 5.1 × 10-4 – Q5KR 
c.f. EV at 48 h). This effect was not seen in normal cells 
Figure 4: Exogenous expression of RECQL5β increases proliferation in normal bladder cells and expression of helicase 
dead RECQL5. A and C. Normal immortalised bladder (NHU hTERT) cells and UCC (EJ) cells transiently transfected with empty 
vector (MOCK), wildtype RECQL5β (Q5) or helicase dead RECQL5β (Q5KR) and western blotted for RECQL5β. B and D. Cell number 
in each of the transfected conditions after 24, 48, 72, 96 and 120 h. Average and standard deviation of 3 independent repeats is shown. 
Significance was calculated using a student’s t-test, ***indicates p<0.001 comparing MOCK to Q5KR transfected EJ cells at 120 h post-
transfection and **indicates p<0.01 comparing MOCK to Q5 transfected NHU hTERT cells at 120 h. E and F. Clonogenic survival fraction 
of EJ cells treated as above for 48 h then replated into mitomycin C (MMC) or camptothecin (CPT). Average and standard deviation of 3 
independent repeats is shown. Significance was calculated using a student’s t-test, **indicates p<0.01 and *indicates p<0.05 comparing Q5 
to Q5KR transfected EJ cells.
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(NHU) (Figure 4B&4C). In contrast to the helicase dead 
Q5 ectopic expression of wildtype Q5 in UCC cells did 
not alter proliferation compared to EV transfected cells 
(Figure 4A&4C), while it’s expression in non-tumour 
NHU hTERT cells significantly increased proliferation 
compared to EV or Q5KR transfected cells (Figure 
4B&4C) (Student’s t-test, p value = 4 × 10-3 – Q5 c.f. EV 
at 96 h).
UCC cells were also transfected with Q5 or Q5KR, 
then replated into MMC or camptothecin for 10 days. 
Colony survival assays, normalised for effect of ectopic 
expression Q5/Q5KR alone, showed that in this cell 
line over expression of Q5KR can sensitize to DNA 
damaging agents (Figure 4E and 4F) (Student’s t-test, 
p value = 0.014 MMC and p=0.0015 camptothecicn – 
Q5KR c.f. Q5).
These data again suggest that RECQL5β helicase 
activity maybe a valid target for specific killing of UCC 
and for sensitising UCC to conventional chemotheraputics. 
Further they provide evidence that overexpression of 
RECQL5 may contribute to increased proliferation and 
thus cellular transformation in bladder cells.
DISCUSSION
To date no inherited cancer predisposition syndrome 
has been associated with RECQL5. However reports of 
alteration in RECQL5 in sporadic cancer are emerging, 
these include polymorphisms associated with cancer [19, 
22–24], one report that RECQL5 mRNA and protein levels 
are reduced in colorectal cancer (CRC) [42] and a recent 
report by our lab showing high levels of RECQL5 are 
associated with aggressive phenotypes and poor survival 
outcomes in breast cancer [25]. In contrast to CRC, here 
RECQL5 mRNA and nuclear RECQL5β protein were 
increased in UCC when compared to normal tissue. This 
is slightly unexpected given that RECQL5 deficient mice 
are cancer-prone and suggests that, like several other 
members of the RECQ helicase family [25, 43], increased 
expression of RECQL5 can also be associated with cancer. 
Normal bladder cells could be induced to proliferate by 
exogenous expression of wildtype but not helicase dead 
RECQL5β demonstrating a potential functional role of 
increased RECQL5β expression in cellular transformation. 
Previously overexpression of RECQL5β has been shown 
to allow cells to overcome replication stress [35] and it 
is possible that an ability to overcome replication stress 
gives cells a selective advantage during tumourigenesis. 
However the consequence of doing so maybe genomic 
instability, as overexpression of RECQL5β also reduces 
replication stress induced checkpoint activation and 
homologous recombination [35]. Interesting in breast 
cancer we previously showed that high RECQL5 protein 
level needed to be associated with low RAD51 protein 
expression to infer poor survival, suggesting a functional 
relationship between RECQL5 and RAD51 pathways 
influences breast cancer tumour progression or response 
to therapy [25].
Consistent with findings in breast cancer [25] 
increased RECQL5 mRNA was associated with poor 
prognosis in bladder cancer, suggesting value as a 
prognostic marker, perhaps with particular value in 
identifying high-grade tumours which are likely to 
progress to more serious disease. In addition RECQL5β 
protein expression tended to have stronger staining in 
higher-grade metastatic disease.
Exogenous expression of RECQL5β in normal 
bladder cells increased proliferation, while expression 
of a helicase dead mutant did not significantly alter 
growth. In contrast no change in growth was seen when 
wildtype The The potential of RECQL5 as a therapeutic 
target has been discussed previously in other cancers 
[25, 34, 35, 44]. RECQL5β levels were increased in 
bladder cancer cells, while overexpression of a helicase 
dead RECQL5 protein or siRNA mediated depletion 
of RECQL5 resulted in reduced cell survival in UCC 
cells. In addition depletion of RECQL5 or expression 
of helicase dead RECQL5 increased cell death in MMC 
and camptothecin treated UCC cells. Taken together 
these data demonstrate the potential of RECQL5 as 
a therapeutic target in UCC. Given that several other 
RECQ helicases have recently been successfully and 
specifically targeted by small molecule inhibitors 
[22, 45], it maybe be possible and timely to develop 
RECQL5 inhibitors for use as chemotherapeutics either 
as monotherapies or combined with conventional DNA 
damaging agents.
In summary we have shown that increased 
expression of RECQL5 protein occurs and is likely 
to contribute to tumourigenesis in UCC and that the 
pharmacological targeting of the helicase activity of 
RECQL5 is a strong target for future small molecule 
inhibitor development.
MATERIALS AND METHODS
Human UCC tissue microarrays
UCC tissue microarrays (BL1002, BL802a, and 
BNC12011) were purchased from US Biomax, Inc. 
TMAs contained 1mm diameter and 5 μM thickness 
cores from formalin-fixed paraffin-embedded (FFPE) 
samples, some samples were sparse and could not 
be analysed. Samples that were analysed are shown 
in Supplementary Table S1, these included 90 
urothelial carcinoma, 4 squamous cell carcinoma, 4 
adenocarcinoma, 7 adjacent normal bladder tissues and 




and Supplementary Table S1).
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Patients and tumours
We selected new freshly frozen primary tumours 
treated at the Royal Hallamshire Hospital Sheffield, 
UK. TUCC were classified using the 2004 WHO/ISUP 
criteria and treated according to standard care [46, 47]. 
For comparison we obtained disease free urothelium from 
patients undergoing radical prostatectomy for prostate 
cancer. All tissues were confirmed using H&E sections 
and micro dissected to obtain cell populations with >80% 
purity. Following resection, all patients were followed 
for progression (defined as a second bladder tumour of 
increased stage or until metastases developed). Patient 
demographics are summarized in Supplementary Table 
S1 of supporting information. Collection of samples was 
performed after obtaining informed consent and within an 
ethics committee approved collection (South Yorks Ethics 
committee 10/H1310/73).
Cell lines
UCC cell lines EJ [48], RT112 [48] and RT4 
[49] were grown in DMEM with 10% fetal calf serum. 
Immortalised normal human urothelium cells [50] were 
grown in Keratinocyte Serum Free Media (KSFM) 
supplemented with epidermal growth factor (EGF) (5 ng/
ml) and bovine pituitary extract (BPE) (50 ng/ml) (Gibco) 
with 30 ng/ml of cholera toxin (Sigma-Aldrich Company 
Ltd, Poole, UK).
RECQL5 helicase expression using IHC
TMAs were deparaffinised and rehydrated in 
distilled water. IHC, antigen retrieval was performed 
using heat-induced epitope retrieval buffer (Sodium 
Citrate Buffer, 10 mM Sodium Citrate, 0.05 % Tween 
20, pH 6). Endogenous peroxidase activity was blocked 
using 3% H2O2. Anti-RECQL5 rabbit polyclonal antibody 
(Sigma-Aldrich; HPA029971) was diluted 1:150 in 2% 
goat serum, 2% casein in PBS. TMAs were incubated with 
primary antibody overnight at 4°C. 3,3-Diaminobenzidine 
substrate was used to visualize RECQ-positive cells. 
TMAs were counterstained with hematoxylin. Nuclear 
staining was scored using an intensity score ranging from 
0 to 3 (0=negative, 1=weak intensity nuclear staining or 
staining<30% nuclei, 2 =medium intensity staining or 
staining <60% nuclei, 3=strong intensity nuclear staining 
in >60% nuclei.
For optimization of IHC EJ cells depleted of 
RECQL5 using pooled siRNA as below were fixed in 
4% paraformaldehyde/PBS overnight, before PFA was 
replaced first with 70% ethanol then with 2% agarose- 
4%formaldehyde and being embedded in wax and 
sectioned (Supplementary Figure S1A), an IgG control 
was also included for these pellets. These demonstrate 
that when RECQL5 is depleted the signal is reduced 
indicating specificity of primary antibody to the antigen 
RECQL5. Second an IgG control was used on a test TMA 
in parallel to each experiment (Supplementary Figure 
S1B), demonstrating that on each occasion the staining is 
dependent on the primary antibody rather than a reaction 
of the secondary antibody. There is also there is also an 
internal negative control of fibroblast nuclei within the 
bladder stroma in the arrays, if staining.
Slides were imaged using an Aperio Slide Scanner. 
Scoring was performed by a trained pathologist. 
Significance was calculated using Stata Data Analysis and 
Statistical Software, Version 12.
Quantitative real-time PCR
RNA from the UCC and normal urothelial cell 
lines (NHU, RT4, RT112 and EJ) and primary UCC and 
normal samples was extracted using the RNeasy Mini Kit 
(Qiagen, Manchester, UK). Approximately 1 × 106 cells 
were used and manufacturer’s instructions were followed 
to isolate 5 – 35 μg of total RNA. cDNA was generated 
from RNA using the Applied Biosciences High Capacity 
cDNA Reverse Transcription Kit. RT-PCR was performed 
using TaqMan probe and primers (Applied Biosystems, 
Grand Island, NY) for RECQL5β (Hs00696986_g1) and 
RECQL5 non isotype specific (Hs00188633_m1), Heat 
shock protein 90kDa alpha (cytosolic), class B member 
1 (HSP90AB1) (Hs03043878_g1), Testis enhanced 
gene transcript protein (TEGT) (Hs01012085_m1) 
and Mitochondrial ATP synthase H+ transporting F1 
complex beta subunit (ATP5B) (Hs00969573_mH) with 
TaqMan Universal PCR Mix (Applied Biosystems) as 
recommended by the manufacturer. The dissociation 
curve was then calculated. ΔCT values were calculated 
normalisation to the median of 4 housekeeping genes 
TEGT, ATP58, HSP90AB and PCNA chosen from 
previous reports in bladder cancer [51]. Fold change was 
calculated using DDCt methods [52]. Outcomes with 
respect to time were plotted using the Kaplan-Meier 
method and compared using a Log rank test within SPSS 
(Vsn. 19.0 SPSS Inc.).
Western blotting
Cells were lysed in lysis buffer (50 mM HEPES, 
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% Glycerol, 
1% Triton X100, Complete Protease inhibitor complex 
(Roche, Welwyn Garden City, UK), Phosphatase inhibitor 
complex 1 and Phosphatase inhibitor complex 2 (Sigma-
Aldrich). 50 μg total protein was resolved on an SDS-
PAGE gel and transferred to Hybond ECL membrane 
(GE Healthcare Life Sciences, Little Chalfont, UK). This 
membrane was immunoblotted with rabbit anti-RECQL5 
(AB91422, 1:2000, Abcam, Cambridge, UK), rabbit 
anti-eLF2α (9722, Cell signalling technology, Danvers, 
MA), rabbit anti-eLF2α-pS51 (9721, Cell signalling 
technology) and rabbit anti-β-ACTIN (A2228, 1:2000, 
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Sigma-Aldrich) or mouse anti-β-tubulin (T8328, 1:1000, 
Sigma-Aldrich), antibodies in 5% milk overnight. After 
addition of the appropriate HRP conjugated secondary 
antibody and further washes, immunoreactive protein 
was visualised using ECL reagents (GE Healthcare Life 
Sciences) following manufacturers’ instructions. Intensity 
was analysed using imageJ image processing software.
Plasmids and siRNA
pcDNA 3.1 plasmids containing human RECQL5β 
cDNA (Q5) and RECQL5KR (RecQL5β cDNA sequence 
with the helicase domain disrupted by a K58R point 
mutation – Q5KR)) were a generous gift from Dr. 
Pavel Janscak (Institute of Molecular Cancer Research, 
University of Zurich)
Q5 si1 was a pool of two predesigned siGenome 
siRNA (RECQL5-01 and RECQL5-03, Thermo 
Scientific, Winsford, UK) designed to target all 3 
isoforms of RECQL5, Q5 si2 was a pool of custom 
oligos (UGAAGAAGGUGGCCGAUAU) and 
(CUGCAAAUGUUGUGGUCAA) designed only to 
target RECQL5β.
Proliferation assays following overexpression 
of RECQL5
1x105 cells were plated 24 hours prior to transfection 
with 2.5 μg of plasmid DNA expressing wildtype 
RECQL5β (Q5) or helicase dead RECQL5β (Q5KR) [35] 
using Lipofectamine 2000 (Invitrogen, Grand Island, NY). 
At various times post transfection cells were trypsinised 
from replica plates, stained with trypan blue and live cells 
counted. On each occasion 8 counts of each condition 
were taken and an average calculated. The experiment 
was repeated on 3 independent occasions and average and 
standard deviations calculated.
Survival assays following siRNA mediated 
depletion of RECQL5
20 μM siRNA against RECQL5/RECQL5β was 
reverse transfected into 1x105 cells using lipofectamine 
RNAiMAX. Cells were left 96 hours before counting as 
above. Relative survival compared to cells transfected 
with a scrambled control was calculated. The experiment 
was repeated on 3 independent occasions and average and 
standard deviations calculated.
Survival in the presence of MMC and 
camptothecin
For analysis of sensitivity to DNA damaging agents, 
cells were treated as above for 48 h prior to replating into 
90 mm dishes in presence of increasing doses of MMC 
and camptothecin and then left 10 days for colonies to 
form before staining with 4% methylene blue in 70% 
methanol and counting. The experiment was repeated 
on 2 independent occasions and average and standard 
deviations calculated.
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